The contribution of different prion protein types and host polymorphisms to clinicopathological variations in Creutzfeldt-Jakob disease

Reviews in Medical Virology

Volumn 22, Issue 4, 2012, Pages 214-229

  Head, Mark W ^a   Ironside, James W ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRION PROTEIN; PROTEINASE;

CLINICOPATHOLOGICAL VARIATION; CODON; CREUTZFELDT JAKOB DISEASE; DISEASE CLASSIFICATION; GENETIC POLYMORPHISM; HUMAN; MOLECULAR GENETICS; NONHUMAN; PATHOGENESIS; PATHOLOGY; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; CREUTZFELDT-JAKOB SYNDROME; HUMANS; POLYMORPHISM, GENETIC; PRIONS;

EID: 84863553708     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.725     Document Type: Review

References (145)

1. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216: 136-144.
2. DeArmond SJ, Prusiner SB. Perspectives on prion biology, prion disease pathogenesis, and pharmacological approaches to treatment. Clinics in Laboratory Medicine 2003; 23: 1-41.
3. Wickner RB, Shewmaker F, Edskes H, et al. Prion amyloid structure explains templating: how proteins can be genes. FEMS Yeast Research 2010; 10: 980-991.
4. Bailey CH, Kandel ER, Si K. The persistence of long-term memory: a molecular approach to self-sustaining changes in learning-induced synaptic growth. Neuron 2004; 44: 49-57.
5. Olanow CW, Prusiner SB. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci USA 2009; 106: 12571-12572.
6. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nature Reviews Neuroscience 2010; 11: 155-159.
7. Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends in Neurosciences 2010; 33: 317-325.
8. Aguzzi A, O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nature Reviews. Drug Discovery 2010; 9: 237-248.
9. Westerrmark GT, Westermark P. Prion-like aggregates: infectious agents in human disease. Trends in Molecular Medicine 2010; 16: 501-507.
10. Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C. De novo induction of amyloid-β deposition in vivo. Molecular Psychiatry 2011. DOI: 10.1038/mp.2011.120.
11. Brown P, Bradley R. 1755 and all that: a historical primer of transmissible spongiform encephalopathy. BMJ 1998; 317: 1688-1692.
12. Gavier-Widen D, Stack MJ, Baron T, Balachandran A, Simmons M. Diagnosis of transmissible spongiform encephalopathies in animals: a review. Journal of Veterinary Diagnostic Investigation 2005; 17: 509-527.
13. Watts J, Balachandran A, Westaway D. The expanding universe of prion diseases. PLoS Pathogens 2006; 2; e26.
14. Yokoyama T, Mhori S. Prion diseases and emerging prion diseases. Current Medicinal Chemistry 2008; 15: 912-916.
15. Ironside J, Ghetti B, Head MW, Piccardo P, Will RG. Prion diseases. In Greenfiled's Neuropathology, Love S, Louis DN, Ellison DW (eds). Hodder Arnold: London, 2008; 1197-1273.
16. Tranulis MA, Benestad SL, Baron T, Kretzschmar H. Atypical prion diseases in humans and animals. Topics in Current Chemistry. DOI: 10.1007/128_2011_161.
17. Mabbott NA, MacPherson GG. Prions and their lethal journey to the brain. Nature Reviews Microbiology 2006; 4: 201-211.
18. Bruce M. TSE strain variation. British Medical Bulletin 2003; 66: 99-108.
19. Moore RC, Hope J, MacBride PA, et al. Mice with gene targeted prion protein alterations show that Prnp, Sinc and Prmi are congruent. Nature Genetics 1998; 18: 118-125.
20. Bessen RA, Marsh RF. Identification of two biologically distinct strains of transmissible mink encephalopathy in hamsters. Journal of General Virology 1992; 73: 329-334.
21. Bessen RA, Marsh RF. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. Journal of Virology 1994; 68: 7859-7868.
22. Gambetti P, Dong Z, Yuan J, et al. Variably protease-sensitive prionopathy: a new sporadic disorder of the prion protein. Annals of Neurology 2008; 63: 697-708.
23. Budka H, Aguzzi A, Brown P, et al. Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathology 1995; 5: 457-466.
24. Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 2009; 132: 2659-2668.
25. Heath CA, Cooper SA, Murray K, et al. Validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. Annals of Neurology 2010; 67: 761-770.
26. Watts JC, Westaway D. The prion protein family: diversity, rivalry, and dysfunction. Biochemica Biophysica Acta 2007; 1772: 654-672.
27. Beck JA, Campbell TA, Adamson G, et al. Association of a null allele of SPRN with variant Creutzfeldt-Jakob disease. Journal of Medical Genetics 2008; 45: 813-817.
28. Lloyd S, Mead S, Collinge J. Genetics of prion disease. Topics in Current Chemistry. DOI: 10.1007_2011_157.
29. Morris RJ, Parkyn CJ, Jen A. Traffic of prion protein between different compartments on the neuronal surface, and the propagation of prion protein. FEBS Letts 2006; 580: 5565-5571.
30. C): its physiological function and role in disease. Biochemica Biophysica Acta 2007; 1772: 629-644.
31. Zhan R, Liu A, Lurs T, et al. NMR solution structure of the human prion protein. Proc Natl Acad Sci USA 2000; 97: 145-150.
32. Palmer MS, Collinge J. Mutation and polymorphisms in the prion protein gene. Human Mutation 1993; 2: 168-173.
33. Alperovitch A, Zerr I, Pocchiari M, et al. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet 1999; 353: 1673-1674.
34. Collinge J, Whitfield J, McKintosh E, et al. Kuru in the 21st century-an acquired human prion disease with very long incubation periods. Lancet 2006; 367: 2068-2074.
35. Bishop MT, Pennington C, Heath CA, Will RG, Knight RSG. PRNP variation in UK sporadic and variant Creutzfeldt-Jakob disease highlights genetic risk factors and a novel non-synonymous polymorphism. BMC Medical Genetics 2009; 10: 146.
36. Mastrianni JA. The genetics of prion diseases. Genetics in Medicine 2010; 12: 187-195.
37. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Annals of Neurology 1999; 46: 224-233.
38. Huillard d'Aignaux J, Costagliola D, Maccario J, et al. Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France. Neurology 1999; 53: 1197-1201.
39. Lee HS, Brown P, Cervenakova L, et al. Increased susceptibility to kuru of carriers of the PRNP methionine/methionine genotype. J Infect Disease 2001; 1834: 192-196.
40. Monari L, Chen SG, Brown P, et al. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: different prion proteins determined by a DNA polymorphism. Proc Natl Acad Sci USA 1994; 91: 2839-2842.
41. Mead S. Prion disease genetics. European Journal of Human Genetics 2006; 14: 273-281.
42. Beck JA, Poulter M, Campbell TA, et al. PRNP allelic series from 19years of prion protein gene sequencing at the MRC Prion Unit. Human Mutation 2010; 31: E1551-E1563.
43. Collinge J, Sidle KCL, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 1996; 383: 685-690.
44. Parchi P, Capellari S, Chen SG, et al. Typing prion isoforms. Nature 1997; 386: 232-234.
45. Parchi P, Zou W, Wang W, et al. Genetic influence on the structural variations of the abnormal prion protein. Proc Natl Acad Sci USA 2000; 97: 10168-10172.
46. Sc in the same brain. Neurology 1999; 53: 2173-2173.
47. Head MW, Bunn TJR, Bishop MT, et al. Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob diseases: UK cases 1991-2002. Annals of Neurology 2004; 55: 851-859.
48. Ghetti B, Piccardo P, Frangione B, et al. Prion protein amyloidosis. Brain Pathology 1996; 6: 127-145.
49. Parchi P, Petersen RB, Chen SG, et al. Molecular pathology of fatal familial insomnia. Brain Pathology 1998; 8: 539-548.
50. Parchi P, Chen SG, Brown P, et al. Differential patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Straussler-Scheinker disease. Proc Natl. Acad Sci USA 1998; 95: 8322-8327.
51. Hainfellner J, Parchi P, Kitamoto T, Jarius C, Gambetti P, Budka H. A novel phenotype in familial Creutzfeldt-Jakob disease: prion protein gene E200K mutation coupled with valine at codon 129 and type 2 protease-resistant prion protein. Annals of Neurology 1999; 45: 812-816.
52. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG. Sporadic and familial CJD: classification and characterisation. British Medical Bulletin 2003; 66: 213-239.
53. Hill AF, Joiner S, Beck JA, et al. Distinct glycoform ratios of protease resistant prion protein associated with PRNP point mutations. Brain 2006; 129: 676-685.
54. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-925.
55. Heath CA, Cooper SA, Murray K, et al. Diagnosing variant Creutzfeldt-Jakob disease: a retrospective analysis of the first 150 cases in the UK. Journal of Neurology, Neurosurgery, and Psychiatry 2011; 82: 646-651.
56. Ironside JW, Head MW, Bell JE, McCardle L, Will RG. Laboratory diagnosis of variant Creutzfeldt-Jakob disease. Histopathol 2000; 37: 1-9.
57. Hilton DA, Fathers E, Edwards P, Ironside JW, Zajicek J. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet 1998; 352: 703-704.
58. Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999; 353: 183-189.
59. Wadsworth JDF, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 2001; 358: 171-180.
60. Head MW, Ritchie D, Smith N, et al. Peripheral tissue involvement in sporadic, iatrogenic, and variant Creutzfeldt-Jakob disease: an immunocytochemical, quantitative and biochemical study. American Journal of Pathology 2004; 164: 143-153.
61. Kaski D, Mead S, Hyare H, et al. Variant CJD in an individual heterozygous for PRNP codon 129. Lancet 2009; 374: 2128.
62. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Creutzfeldt-Jakob disease and blood transfusion: results of the UK transfusion medicine epidemiology review study. Vox Sanguinus 2006; 91: 221-230.
63. Wroe SJ, Pal S, Siddique D, et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006; 368: 2061-2067.
64. Head MW, Yull HM, Ritchie DL, Bishop MT, Ironside JW. Pathological investigation of the first blood donor and recipient pair linked by transfusion-associated variant Creutzfeldt-Jakob disease. Neuropathol Applied Neurobiol 2009; 35: 433-436.
65. Peden AH, Head MW, Ritchie DR, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364: 527-529.
66. Peden A, McCardle L, Head MW, et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16: 296-304.
67. Ironside JW, Bishop MT, Connolly K, et al. Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ 2006; 332: 1186-1188.
68. Brandel JP, Heath CA, Head MW, et al. Variant Creutzfeldt-Jakob disease in France and the United Kingdom: evidence for the same agent strain. Annals of Neurology 2009; 65: 249-256.
69. Notari S, Moleres F, Hunter SB, et al. Multiorgan detection and characterisation of protease-resistant prion protein in a case of variant CJD examined in the United States. PLoS One 2010; 5: e8765.
70. Head MW, Tissingh G, Uitdenhaag BMJ, et al. Sporadic Creutzfeldt-Jakob disease in a young Dutch valine homozygote: atypical molecular phenotype. Annals of Neurology 2001; 50: 258-261.
71. res glycosylation in Creutzfeldt-Jakob disease-implications for the dissemination and diagnosis of human prion strains. PLoS One 2008; 3: e2786.
72. Lasmezas CI, Deslys JP, Demaimay R, et al. BSE transmission to macaques. Nature 1996; 381: 743-744.
73. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997; 389: 498-501.
74. Scott MR, Will R, Ironside J, et al. Compelling transgenic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci USA 1999; 96: 15137-15142.
75. Ritchie DL, Boyle A, McConnell I, Head MW, Ironside JW, Bruce ME. Transmission of variant Creutzfeldt-Jakob disease from brain and lymphoreticular tissue show uniform and conserved bovine spongiform encephalopathy-related phenotypic properties on primary and secondary passage in wild-type mice. Journal of General Virology 2009; 90: 3075-3082.
76. Bishop MT, Hart P, Aitchison L, et al. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurology 2006; 5: 393-398.
77. Bishop MT, Ritchie DR, Will RG, et al. No major change in vCJD agent strain after secondary transmission via blood transfusion. PLoS One 2008; 3: e2878.
78. Sc. The Journal of Pathology 2007; 213: 21-26.
79. Sc type and PRNP genotype in an in-vitro conversion assay. NeuroReport 2008; 19: 1783-1786.
80. Jones M, Peden AH, Yull H, et al. Human platelets as a substrate source for the in vitro amplification of abnormal prion protein (PrP) associated with variant Creutzfeldt-Jakob disease. Transfusion 2009; 49: 376-384.
81. Jones M, Wight D, Barron R, et al. Molecular model of prion transmission to humans. Emerging Infectious Diseases 2009; 15: 2013-2016.
82. Parchi P, Capellari S, Chin S, et al. A subtype of sporadic prion disease mimicking fatal familial insomnia. Neurology 1999; 52: 1757-1763.
83. Minor P, Newham J, Jones N, et al. and the WHO Working Group in international reference materials for the diagnosis and study of transmissible spongiform encephalopathies. Journal of General Virology 2004; 85: 1777-1784.
84. Sc types in individuals with Creutzfeldt-Jakob disease. Lancet Neurology 2005; 4: 805-814.
85. Sc profiling in sporadic Creutzfeldt-Jakob disease. PLoS Medicine 2006; 3: e14.
86. res type 1/type 2 dichotomy in Creutzfeldt-Jakob disease. PLoS Pathogens 2008; 4: 1000026.
87. Cali I, Castellani R, Alshekhlee A, et al. Co-existence of scrapie prion protein types 1 and 2 in sporadic Creutzfeldt-Jakob disease: its effect on the phenotype and prion-type characteristics. Brain 2009: 132: 2643-2658.
88. Sc types: an updated classification. Acta Neuropathologica 2009: 118: 659-671.
89. res in sporadic Creutzfeldt-Jakob disease MM1. American Journal of Pathology 2011; 178: 1309-1315.
90. Sc. Journal of Neuropathology and Experimental Neurology 2005; 64: 902-909.
91. Head MW, Ironside JW. Sporadic Creutzfeldt-Jakob disease: discrete subtypes or a spectrum of disease? Brain 2009; 132: 2629-2629.
92. Bishop MT, Will RG, Manson JC. Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties. Proc Natl Acad Sci USA 2010; 107: 12005-12010.
93. Head MW, Knight R, Zeidler M, Yull H, Barlow A, Ironside JW. A case of protease sensitive prionopathy in a patient in the UK. Neuropathol Applied Neurobiol 2009; 35: 628-632.
94. Jansen C, Head MW, van Gool WA, et al. The first case of protease-sensitive prionopathy (PSPr) in the Netherlands: a patient with an unusual GSS-like clinical presentation. Journal of Neurology, Neurosurgery, and Psychiatry 2010; 81: 1052-1055.
95. Zou WQ, Puoti G, Xiao X, et al. Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Annals of Neurology 2010; 68: 162-172.
96. Giaccone G, Di Fede G, Mangieri M, et al. A novel phenotype of sporadic Creutzfeldt-Jakob disease. Journal of Neurology, Neurosurgery, and Psychiatry 2007; 78: 1379-1382.
97. Head MW, Lowrie S, Chohan G, Knight R, Scoones DJ, Ironside JW. Variably protease-sensitive prionopathy in a PRNP heterozygous UK patient with co-existing tau, α-synuclein and Aβ pathology. Acta Neuropathologica 2010; 120: 821-823.
98. Rodriguez-Martinez AB, Garrido JM, Zarranz JJ, et al. A novel form of human disease with a protease-sensitive prion protein and heterozygosity methionine/valine at codon 129: case report. BMC Neurology 2010; 10: 99.
99. Takashima S, Tateishi J, Taguchi Y, Inoue H. Creutzfeldt-Jakob disease with florid plaques after cadaveric dural graft in a Japanese woman. Lancet 1977; 350: 865-866.
100. Billette de Villemeur T, Gelot A, Deslys JP, et al. Iatrogenic Creutzfeldt-Jakob disease in three growth hormone recipients: a neuropathological study. Neuropathol Applied Neurobiol 1994; 20: 111-117.
101. Deslys JP, Jaegly A, Huillard d'Aignaux J, Mouthon F, Billette de Villemeur T, Dormond D. Genotype at codon 129 and susceptibility to Creutzfeldt-Jakob disease. Lancet 1998; 351: 1251.
102. Satoh K, Muramato T, Tanaka T, et al. Association of an 11-12kDa protease-resistant prion protein fragment with subtypes of dura mater graft-associated Creutzfeldt-Jakob disease and other prion diseases. Journal of General Virology 2003; 84: 2885-2893.
103. Heath CA, Barker RA, Esmonde TFG, et al. Dura mater-associated Creutzfeldt-Jakob disease: experience from surveillance in the UK. Journal of Neurology, Neurosurgery, and Psychiatry 2006; 77: 880-882.
104. Brandel JP, Preece M, Brown P, et al. Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK. Lancet 2003; 362: 129-130.
105. Brown P, Preece M, Brandel JP, et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2000; 55: 1075-1081.
106. Brown P, Brandel JP, Preece M, Sato T. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology 2006; 67: 389-393.
107. Lasmezas CI, Fournier JG, Nouvel V, et al. Adaptation of bovine spongiform encephalopathy agent to primates and comparison with Creutzfeldt-Jakob disease: implications for human health. Proc Natl Acad Sci USA 2001; 98: 4142-4147.
108. Wadsworth JDF, Joiner S, Lineham JM, et al. Kuru prions and sporadic Creutzfeldt-Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proc Natl Acad Sci USA 2008; 105: 3885-3890.
109. Kovacs GG, Trabattonni G, Hainfellner JA, Ironside JW, Knight RSG, Budka H. Mutations of the prion protein gene: phenotypic spectrum. Journal of Neurology 2002; 249: 1567-1582.
110. Capellari S, Strammiello R, Saverioni D, Kretzschmar H, Parchi P. Genetic Creutzfeldt-Jakob disease and fatal familial insomnia: insights into phenotypic variability and disease pathogenesis. Acta Neuropathologica 2011; 121: 21-37.
111. Parchi P, Capellari S, Gambetti P. Intracerebral distribution of the abnormal isoform of the prion protein in sporadic Creutzfeldt-Jakob disease and fatal insomnia. Micro Res Tech 2000; 50: 16-25.
112. Piccardo P, Seiler C, Dlouhy SR, et al. Proteinase-K-resistant prion protein isoforms in Gerstmann-Straussler-Scheinker disease (Indiana kindred). Journal of Neuropathology and Experimental Neurology 1996; 55: 1157-1163.
113. Piccardo P, Dlouhy SR, Lievens PMJ, et al. Phenotypic variability of Gerstmann-Straussler-Scheinker disease is associated with prion protein heterogeneity. Journal of Neuropathology and Experimental Neurology 1998; 57: 979-988.
114. Piccardo P, Liepnieks JJ, Willaim A, et al. Prion proteins with different conformations accumulate in Gerstmann-Straussler-Scheinker disease caused by A117V and F198S mutations. American Journal of Pathology 2001; 158: 2201-2207.
115. sc heterogeneity in inherited prion diseases with the D178N mutation. Annals of Neurology 2004; 57: 909-910.
116. Kovacs GG, Seguin J, Quadrio I, et al. Genetic Creutzfeldt-Jakob disease associated with the E200K mutation: characterisation of a complex proteinopathy. Acta Neuropathologica 2011; 121: 39-57.
117. Chen SG, Parchi P, Brown P, et al. Allelic origin of the abnormal prion protein isoform in familial prion diseases. Nature Med 1997: 3: 1009-1015.
118. Wadsworth JDF, Joiner S, Lineham JM, et al. Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein. Brain 2006; 129: 1557-1569.
119. Telling GC, Parchi P, DeArmond SJ, et al. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 1996; 274: 2079-2082.
120. Mastrianni J, Nixon R, Layzer R, et al. Prion protein conformation in a patient with sporadic fatal insomnia. New Eng J Med 1999; 340: 1630-1638.
121. Sc in vivo. Journal of Biological Chemistry 2007; 282: 35878-35886.
122. Picardo P, Manson JC, King D, Ghetti B, Barron RM. Accumulation of prion protein in the brain that is not associated with transmissible disease. Proc Natl Acad Sci USA 2007; 104: 4712-4717.
123. Chesebro B, Trifilo M, Race R, et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 2005; 308: 1435-1439.
124. Chesebro B, Race B, Meade-White K, et al. Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein anchoring. PLoS Pathogens 2010; 6: e1000800.
125. Ghetti B, Piccardo P, Spillantini MG, et al. Vascular variant of prion protein cerebral amyloidosis with τ-positive tangles: the phenotype of the stop codon 145 mutation in PRNP. Proc Natl Acad Sci USA 1996; 93: 744-748.
126. Holton JL, Mead S, Gandhi S, et al. Clinicopathological observations associated with a novel truncated mutation of PRNP. Neuropathol Applied Neurobiol 2010; 36(Suppl. 1): 2.
127. Jansen C, Parchi P, Capellari S, et al. Prion protein amyloidosis with divergent phenotype associated with two novel nonsense mutations in PRNP. Acta Neuropathologica 2010; 119: 189-197.
128. Jayadev S, Nochlin D, Poorkaj P, et al. Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype. Annals of Neurology 2011; 69: 712-720.
129. Pan T, Colucci M, Wong BS, et al. Novel differences between two human prion strains revealed by two-dimensional gel electrophoresis. Journal of Biological Chemistry 2001; 276: 37284-37288.
130. Silviera JR, Raymond GJ, Hughson AG, et al. The most infectious prion particles. Nature 2005; 437: 257-261.
131. Kristiansen M, Deriziotis P, Dimcheff DE, et al. Disease-associated prion protein oligomers inhibit the 26S proteasome. Molecular Cell 2007; 26: 175-188.
132. Sasaki K, Minaki H, Iwaki T. Development of oligomeric prion protein aggregates in a mouse model of prion disease. The Journal of Pathology 2009; 219: 123-130.
133. Sc have different aggregation sizes in methionine homozygotes with sporadic, iatrogenic and variant Creutzfeldt-Jakob disease. Journal of General Virology 2005; 86: 237-240.
134. Cali I, Castellani R, Yuan J, et al. Classification of sporadic Creutzfeldt-Jakob disease revisited. Brain 2006; 129: 2266-2277.
135. Yuan J, Xiao X, McGeehan J, et al. Insoluble aggregates and protease-resistant conformers of prion protein in uninfected human brains. Journal of Biological Chemistry 2006; 281: 34848-34858.
136. Choi YP, Groener A, Ironside JW, Head MW. Correlation of polydispered prion protein and characteristic pathology in the thalamus in variant Creutzfeldt-Jakob disease: implication of small oligomeric species. Brain Pathology 2011; 21: 298-307.
137. Safar JG, Geschwind MD, Deering C, et al. Diagnosis of human prion diseases. Proc Natl Acad Sci USA 2005; 102: 3501-3506.
138. Choi YP, Groener A, Ironside JW, Head MW. Comparison of the level, distribution and form of disease-associated prion protein in variant and sporadic Creutzfeldt-Jakob disease brain using conformation-dependent immunoassay and Western blot. Journal of General Virology 2011; 92: 727-732.
139. Sc molecules with different conformations. Nature Med 1998; 4: 1157-1165.
140. Legname G, Nguyen HOB, Peretz D, Cohen FE, DeArmond SJ, Prusiner SB. Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc Natl Acad Sci USA 2006; 103: 19105-19110.
141. Colby DW, Giles K, Legname G, et al. Design and construction of diverse mammalian prion strains. Proc Natl Acad Sci USA 2009; 106: 20417-20422.
142. Choi YP, Peden AH, Groener A, Ironside JW, Head MW. Distinct stability states of disease-associated human prion protein identified by conformation-dependent immunoassay. Journal of Virology 2010; 84: 12030-12038.
143. Sc. PLoS One 2011; 5: e12723.
144. Castilla J, Saa P, Morales R, Abid K, Maudrell K, Soto C. Protein misfolding cyclic amplification for diagnosis and prion propagation studies. Methods in Enzymology 2006; 412: 3-21.